Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CovX Research LLC

Division of Pfizer Inc.
www.covx.com

Latest From CovX Research LLC

Financings Of The Fortnight Ponders Sequester Fallout Potential For Biotech

Plus news on recent financings by Tesaro, Ablynx, Spring Bank Pharmaceuticals and Daiichi Sankyo.

Business Strategies

Peptide Therapeutics' Rising Tide

As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.
BioPharmaceutical

Merck's Head-long Leap into Follow-On Biologics

Merck outlined ambitious and capital-intensive plans for a biosimilars business at its annual investor day in early December. The company aims to leverage its 2006 acquisition of GlycoFi to launch six or more follow-on biologics between 2012 and 2017. The news shifts the Big Pharma in an entirely new direction, one that pharmaceutical companies--with the exception of Novartis AG's Sandoz division--have largely stayed away from.
BioPharmaceutical Business Strategies

Pfizer's Increasingly Specialist Focus

Pfizer's brand-new oncology business unit appears to be the linchpin in its transformation from primary care behemoth to specialty powerhouse. The Big Pharma also followed this up with the announcement that it was cutting early-stage R&D programs focused on obesity, bone health, and what has been its mainstay--cardiovascular disease. Together, these moves should be viewed as the most extreme example of the industry's flight from primary care medicine into the safer haven of specialty-focused pharmaceuticals,
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Shehan Dissanayake, PhD, Chmn. & CEO
    Rodney Lappe, PhD, CSO
  • Contact Info
  • CovX Research LLC
    Phone: (858) 964-2000
    9381 Judicial Drive
    Ste. 200
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register